

CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel: +91-44-4554 1480 / 81; Fax: +91-44-4554 1482
Web: www.cngsn.com; Email: info@cngsn.com

Dr. C.N. GANGADARAN B.Com., FCA, MBIM (Lond.), Ph.d

S. NEELAKANTAN B.Com., FCA

R. THIRUMALMARUGAN M.Com., FCA

B. RAMAKRISHNAN B.Com., Grad. CWA, FCA

V. VIVEK ANAND B.Com., FCA CHINNSAMY GANESAN B.Com., FCA, DISA (ICAI)

D. KALAIALAGAN B.Com., FCA, DISA (ICAI)

K. PARTHASARATHY B.Com., FCA

NYAPATHY SRILATHA M.Com., FCA, PGDFM

E.K. SRIVATSAN B.Com., FCA

INDEPENDENT AUDITOR'S REPORT

To

The Partners, Argus Salud Pharma LLP Chennai-17.

Report on the Financial Statements

We have audited the accompanying financial statements of Argus Salud Pharma LLP (the LLP), which comprises the Balance Sheet as at March 31, 2018, the Statement of Profit and Loss for the year then ended and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of these financial statements that gives true and fair view of the financial position and financial performance of the LLP in accordance with the Accounting Standards issued by the Institute of Chartered Accountants of India. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements.



An audit involves performing procedures to obtain audit evidence about the amounts and disclosure in the financial statements. These procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessment, the auditor considers internal control relevant to the LLP's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing opinion on the LLP's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for audit opinion.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements, give the information required by the Limited Liability Partnership Act, 2008 and Limited Liability Partnership Rules, 2009 (As Amended) in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the LLP as at March 31, 2018; and its net Profit for the year ended on that date

Report on Other Legal and Regulatory Requirements

CHENNA

We report that:

- We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- 2. In our opinion proper books of account as required by law have been kept by the LLP so far as it appears from our examination of those books.
- The Balance Sheet and the Profit and Loss Account, dealt with by this Report are in agreement with the books of account.
- 4. In our opinion, the aforesaid financial statements comply with the Accounting Standards issued by ICAI.

Place: Chennai Date: 25-05-2018

For M/s CNGSN & Associates LLP Chartered Accountants

Firm Regn.No: 4915S/S200036

K. Parthasarathy

Partner

Membership No: 018394

ARGUS SALUD PHARMA LLP BALANCE SHEET AS AT MARCH 31, 2018

BALANCE	SHEET	AS AT MARCH	H 31, 2018		
			As at		As at
	Notes		31-03-2018		31-03-2017
			Rs.		Rs.
SOURCES OF FUNDS					
SHARE HOLDERS' FUNDS					
Partners' Capital Account	1				
Caplin Point Laboratories Ltd		99,00,000		99,00,000	
May India Properties P Ltd		10,000		10,000	99,10,000
,			99,10,000		
Partners' Share of Profit / (Loss)	2				
Caplin Point Laboratories Ltd		(26,86,169)		463,58,650	
May India Properties P Ltd		7,19,081		27,21,881	490,80,531
,			(19,67,088)		
				ľ	
TOTAL			79,42,912		589,90,531
PLICATION OF FUNDS					
CURRENT ASSETS, LOANS & ADVANCES					
Sundry Debtors	3		a a		451,71,780
Cash & Bank balances	4		58,23,369		88,20,513
Loans, Advances & Deposits	5		21,39,543		73,98,590
•			79,62,912		613,90,883
CURRENT LIABILITIES & PROVISIONS					
Current Liabilities	6		2		18,38,356
Provisions	7		20,000		5,61,996
11001310113	′		20,000		24,00,352
T CURRENT ASSETS			79,42,912		589,90,531
TOTAL			79,42,912		589,90,531

The accompanying notes are an integral part of the stand alone financial statements.

CHENNA

As per our report of even dated attached

for CNGSN & Associates

Chartered Accountants

Firm Registration No: 4915S/ S200036

K. PARTHASARATHY

Partner

ICAI Membership No: 018394

Place : Chennai Date : May 25, 2018 For and on behalf ARGUS SALUD PHARMA LLP

May India Property Pvt Ltd

Designated Partner

Caplin Point Laboratories Ltd Designated Partner

	ARGUS SALUD P		
STATEMENT OF PROFIT AN	ID LOSS FOR THE I	INANCIAL YEAR ENDED MA	
		For the Year ended	For the Year ended
		31-03-2018	31-03-2017
	Notes	11	
		Rs.	Rs.
INCOME			
Gross Sales (Less Returns)		s	1711,57,864
Less: Excise Duty			S#.
Net Sales		*	1711,57,864
Export Incentives		*	49,91,709
Other Income	8	32,670	31,52,829
TOTAL		32,670	1793,02,402
IOTAL		32,070	1750,02,402
EXPENSES			
Cost of Goods Sold	9		1012,75,421
Direct Expenses	10	1,76,902	14,01,228
Payments to and Provision for employees	11	37,600	13,07,271
Administrative Expenses	12	25,92,873	132,84,640
Interest and Finance Charges	13	25,152	1,15,928
Selling Expenses	14	-	15,54,543
TOTAL		28,32,527	1189,39,032
PROFIT BEFORE DEPRECIATION AND TAX		(27,99,857)	603,63,370
		(=,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,-
Depreciation and Amortisation		.	3,55,422
PROFIT BEFORE TAX		(27,99,857)	600,07,948
Provision for Taxation - Current			(318,27,283)
- Earlier years			(010/27/200)
- Deferred Tax		150	
Add: MAT credit entitlement		(27.00.257)	701.00.66
PROFIT AFTER TAX		(27,99,857)	281,80,665
Balance carried to Partners'Capital a/c		(27,99,857)	281,80,665
		(27.27.5	204 ==
Caplin Point Laboratories Ltd		(27,97,057)	281,52,484
May India Properties P Ltd		(2,800)	28,181
		(27,99,857)	281,80,665

The accompanying notes are an integral part of the stand alone financial statements.

For and on behalf ARGUS SALUD PHARMA LLP

As per our report of even dated attached

for CNGSN & Associates

Chartered Accountants

Firm Registration No: 4915S/ S200036

K. PARTHASARATHY

Partner

ICAI Membership No: 018394

CHENNAL

ASSOCIA

Place : Chennai Date: May 25, 2018

May India Property Pvt Ltd Designated Partner

Caplin Point Laboratories Ltd Designated Partner

Note 1 PARTNERS' SHARE CAPITAL		As at 31-03-2018 Rs.		As at 31-03-2017 Rs.
Caplin Point Laboratories Ltd May India Properties P Ltd	99,00,000	99,10,000	99,00,000 10,000	99,10,000
		99,10,000		99,10,000

Note 2 PARTNERS' SHARE of Profit		As at 31-03-2018 Rs.		As at 31-03-2017 Rs.
Caplin Point Laboratories Ltd Opening	463,58,650		786,75,941	
For the year	(27,97,057)		281,52,484	
	435,61,593		1068,28,423	
Less: Amount transferred from Partners Current Account	462,47,762	(26,86,169)	604,69,773	463,58,650
May India Properties P Ltd				
Opening	27,21,881		26,93,701	
For the year	(2,800)		28.180	
/	27,19,081		27,21,881	
Less: Amount transferred from Partners Current Account	20,00,000		(*)	27,21,881
		7,19,081		
		(19,67,088)		463,58,650

Note 3 SUNDRY DEBTORS	As at	As at
	31-03-2018	31-03-2017
	Rs.	Rs.
(i) Debts outstanding for a period exceeding six months		
Unsecured and Considered Good	==	
Unsecured and Considered Doubtful	18	.75.0
(ii) Other Debts		
Unsecured and Considered Good		451,71,780
Unsecured and Considered Doubtful	:4	=
		451,71,780

	As at	As at
Note 4 CASH & BANK BALANCES	31-03-2018	31-03-2017
	Rs.	Rs.
(i) Cash on Hand	50,021	50,021
(ii) Balance with banks		
in Current Accounts	56,68,348	85,71,795
in Deposit Accounts	1,05,000	1,98,697
	58,23,369	88,20,513

Note 5 LOANS, ADVANCES & DEPOSITS	As at 31-03-2018	As at 31-03-2017
	Rs.	Rs.
(Unsecured, considered good unless otherwise stated)		
Advances Recoverable in cash or in kind or		
for value to be received		
Deposits with Statutory / Govt. Authorities		
Balance with Sales Tax Authorities	9,70,988	17,90,141
Advances - Others	8,76,427	48,69,339
Deposits	2,92,128	7,39,110
•	21,39,543	73,98,590

	As at	As at
Note 6 CURRENT LIABILITIES	31-03-2018	31-03-2017
	Rs.	Rs.
Sundry Creditors - Goods		14,84,495
- Expenses	₩ ₩	3,53,318
- Capital goods	F 1	2
Sundry Creditors - Others	5	543
		18,38,356

As at 31-03-2018 Rs.	As at 31-03-2017 Rs.
20,000	5,61,996 5,61,996
	31-03-2018 Rs.



Notes to the Standalone financial statements for the Year ended March 31, 2018

Notes to the Standalone financial statements for the Year ended March 31, 2018

	For the Year ended	For the Year ended	
Note 8 INDIRECT INCOME	31-03-2018	31-03-2017	
Interest Income Exchange Fluctuation Income (nett) Miscellancous income	Rs. 32,670	Rs. 20,96,333 8,59,471 1,97,025	
viiscenaneous income	32,670	31,52,829	

	For the Year ended	For the Ye	ar ended
Note 9 COST OF GOODS SOLD	31-03-2018 Rs.		31-03-2017 Rs.
Opening Stock:			
Raw Materials	2	30,50,386	
Work-in-Progress	₩	35,80,099	
Finished Goods	2	25,41,440	91,71,925
Add: Purchases:			
Raw Materials (Less Returns)			
Finished Goods		921,03,496	
			921,03,496
Less: Closing Stock:		1	
Raw Materials	* *	1	
Work-in-Progress	: * :	1 1	
Finished Goods	*		
			1012,75,421

	For the Year ended	For the Year ended	
Note 10 DIRECT EXPENSES	31-03-2018 Rs	31-03-2017 Rs.	
Manufacturing Expenses		8,58,597	
Power and Fuel	1,76,902	5,42,631	
	1,76,902	14,01,228	

	For the Year ended	For the Year ended	
Note 11PAYMENTS TO AND PROVISION FOR EMPLOYEES	31-03-2018	31-03-2017	
	Rs.	Rs.	
Salaries, Wages & Bonus		6,14,227	
Contribution to Provident Fund and other funds		55,538	
Staff Welfare	37,600	6,37,506	
	37,600	13,07,271	

	For the Year ended	For the Year ended	
Note 12 ADMINISTRATIVE OVERHEADS	31-03-2018	31-03-2017	
	Rs	Rs.	
Telephone Expenses	8,889	72,318	
Donations		5,200	
Professional and Consultancy	79,825	3,03,781	
Rates & Taxes		74,931	
Bad debts		38,50,168	
Subscriptions	27,520	20,988	
Travelling & Conveyance	2,61,804	6,22,537	
Audit fees	20,000	80,000	
Insurance	* 1	1,38,619	
Repairs and Maintenance		1	
- Building	× 1	040	
- Others	6,28,594	4,37,370	
Rent & Amenities	53,068	11,57,810	
Loss on sale of assets	*	43,44,798	
Exchange Fluctuation Income (nett)	13,66,755)*·	
Sundry Expenses	1,46,418	21,76,120	
	25,92,873	132,84,640	

	For the Year ended	For the Year ended	
Note 13 INTEREST AND FINANCE CHARGES	31-03-2018	31-03-2017	
	Rs.	Rs.	
Interest - on Term Loans - Others	-	233	
Bank Charges	25,152	1,15,695	
	25,152	1,15,928	

	For the Year ended	For the Year ended	
Note 14 - SELLING OVERHEADS	31-03-2018	31-03-2017	
	Rs.	Rs.	
Advertisement	(4)	3,200	
reight outwards	14	4,20,526	
Other Selling Expenses	5-	11,30,817	
		15,54,543	



ARGUS SALUD PHARMA LLP

SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2018

A. SIGNIFICANT ACCOUNTING POLICIES

1. Basis of preparation of financial statements

The accounts are prepared on historical costs convention and in accordance with the accounting principles generally accepted in India comprising the accounting standards issued by the Institute of Chartered Accountants of India and the provisions of the Companies Act, 1956. The Financial Statements are drawn up on accrual basis.

2. Recognition of Income and Expenditure

The firm adopts mercantile system of accounting and recognizes income and expenditure on accrual basis in accordance with the applicable accounting standards

3. Revenue Recognition

Sale of goods is recognized when the risk and rewards of ownership are passed on to the customers, which is generally on dispatch of goods. Gross sales include excise duty but exclude value added tax/sales tax. Export sales are accounted for on the basis of date of bill of lading.

4. Fixed Assets

Fixed assets are valued at original cost of acquisition less depreciation. The actual cost capitalized includes freight, installation cost, duties and taxes, and other incidental expenses attributable to bringing the asset to its working condition.

5. Depreciation

- a. Depreciation on Fixed Assets is calculated on Straight Line method at rates prescribed in Schedule XIV of the Companies Act, 1956, on original cost of the asset. Additions to fixed assets costing less than Rs. 5000/- are fully charged off as depreciation in the year of addition.
- b. The cost and accumulated depreciation for fixed assets sold, retired or otherwise disposed off are removed from the stated values and the resulting gains and losses are included in the Profit and Loss account.
- c. Depreciation has been calculated, on additions, in pro-rata to the number of months for which they have been in existence.

6. Foreign Currency Transactions

a. Foreign currency transactions are translated at exchange rates prevailing on the date of transactions.

b. Foreign currency monetary assets and liabilities are reported at the closing rate. Gain and losses arising on account of difference in foreign exchange rates on settlement/translation of Monetary Assets and Liabilities on the closing date are recognized in the Profit and Loss Account.

7. Inventories

- a. Raw material, Packing materials, stores and spares are valued at cost including duties and taxes, exclusive of MODVAT credit. The cost is arrived at FIFO basis.
- b. The finished goods inventories are valued on the principles of cost or net realizable value whichever is lower. The cost includes the cost of raw materials, packing materials and other related expenses.
- c. Work in progress is valued on the same basis as finished goods and is inclusive of their cost of raw materials, packing materials and other related expenses.
- d. Value of closing stock as on 31st March 2017 is as certified by the management.

8. Retirement benefits

a. Defined Contribution Plans

Contributions paid/payable under defined contribution plans are recognized in the Profit and Loss Account each year. Contribution plan is for Provident Fund administered and managed by the Government of India. The Company makes monthly contributions and has no further obligations under the plan beyond its contributions

b. Short-term employment benefits

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by employees is recognized during the period when the employee renders the service. These benefits include compensated absences such as paid annual leaves and performance incentives.

9. Leases

Lease of assets where the less or effectively retains all the risks and rewards of ownership are classified as operating leases. Lease payments under operating leases are recognized as expenses on accrual basis in accordance with the respective lease agreements.

- 10. Contingent liabilities are not provided for, but disclosed in the Notes on Accounts
- 11. The Company is operating in one segment of "pharmaceutical formulations".



B. NOTES ON ACCOUNTS

1. Contingent Liabilities

(a) Outstanding Bank Guarantee given to the Customs department and others Rs. 1,47,800/- (Previous Year Rs. 1,47,800/-)

2. Dues to Micro, Small and Medium Enterprises

The Firm has not received information from Vendors regarding their status under the Micro, Small and Medium Enterprises Development Act 2006 and hence disclosure relating to amount unpaid as at the year end together with Interest Paid / Payable under this Act have not been given.

3. Balances with Scheduled banks in deposit accounts includes:

- (a) Deposits under lien towards Bank Guarantee Rs. 0/- (Rs. 7,49,089/-)
- 4. Balances of debtors, loans, advances and deposits, including items which are subject to confirmation, have, in the opinion of the management, a value on realization in the ordinary course of business at least equal to the amount at which they are stated and creditors are stated at the value which they are liable to be paid.

5. Auditors' Remuneration comprises of fees:

5. Auditors Remuneration comprises of fees.	In Rs. For the Year ended March 31, 2018	In Rs. For the Year ended March 31, 2017
For Statutory Audit	10000	70000
For Tax Audit	10000	10000
Total	20000	80000

6. CIF Value of Imports

•	In Rs.	In Rs.
	For the year end March 31, 201	•
Raw materials ,Finished Goods	NIL	NIL
Capital Goods	NIL	NIL

7. Earnings in Foreign Exchange (On Accrual basis)

FOB Value of Exports –

Rs. Nil /- (Previous Year Rs. 15,97,04,440/-)



8. Value of consumption of imported and indigenous materials and components

	For the year ended M 2018	arch 31, Fo 201	or the year ende 7	d March 31,
	Rs.	%	Rs.	%
Imported	NIL	%	NIL	%
Indigenous	NIL	%	NIL	%

9. Licensed and Installed Capacity and actual production

	Annual Licensed / Installed Capacity	Actual Production	Annual Licensed / Installed Capacity	Actual Production
	2017-18	2017-18	2016-17	2016-17
Tablets	₩.		:#X	-
Capsules	3	3	120	*
Ointments/Cream			200	.
Liquids	-	i i	-	-

Qty in units in lakhs

10. Details regarding purchase of Traded Goods

	2017	'-18	2016	5-17	
Category	Qty	Qty	Qty	Value	
	Nos in Lakhs	Nos in Lakhs	Nos in Lakhs	Rs. In Lakhs	
Tablets	:=:	:#X	315.94	524.43	
Capsules	(*)	(#X)	,59	85.12	
Liquids	:=:	(#3)	2.39	12.46	
Injection	:	: * :	2.23	88.99	
Ointments		:=:	1.80	36.89	
Softgels	[2]	:=:	19.46	24.24	
Syrup	541	(#:	6.10	143.05	
Others	(a)	(2)	.12	6.03	
Total	121	·	354.19	921.21	



11. Sale of Product comprises

	Manufactured Goods			Traded Goods					
Category	201	7-18	201	2016-17		2017-18		2016-17	
	Qty	Value	Qty	Value	Qty	Value	Qty	Value	
Tablets	3		9	(8	¥.	2	315.94	924.05	
Capsules	iæ!	-		<u> </u>	- 2	Ē	.59	141.86	
Liquids	-	-		1,51	. .		2.39	20.76	
Injectables	<u>:=:</u>	-		(e	*		2.23	148.33	
Ointments	S#3	-	=	16	ä	ā	1.80	61.48	
Softgels	(=)	-	×	14.	-	*	19.46	40.40	
Syrup							6.10	250.08	
Others	ē	9	ŝ	-	4	#	.12	10.05	
Total	36	2	=	<u> </u>	=	2	354.19	1597.04	

12. Details of Closing Stock at

	MANUFACTURED GOODS				Traded Goods			
	20	17-18	20	16-17	201	7-18	2	016-17
CATEGORY	Qty	Value	Qty	Value	Qty	Value	Qty	Value
Tablets	1945		.(€	30	-	*	20 5	
Capsules	16	4	TA	(a)	2	2	528 L	2
Ointments	#	2.0	19:		表		150	15
Liquids	-	a	9	(4)	-	띹	140	ar a
OTHERS	×	# 3	=.	80	*	=	5#8	⊞ ?
Total	ĕ	*	- 4	8	2	-	宇	12 1

13. Operating Leases

The company has entered into cancelable lease agreements for office facilities, office and residential premises of employees. Lease payments recognized in the Profit & Loss Account for the year Rs.53,068/- The Company has not entered into any non cancelable operating leases and finance leases.

- 14. Disclosure in accordance with the Accounting Standard 18 "Related Party disclosures" issued by the Institute of Chartered Accountants of India as identified by the company and relied upon by the auditors.
 - (a) Related parties and nature of relationship
 - Caplin Point Laboratories Ltd

(b) Key management personnel

■ Mr. Manish – Production Executive

(c) Transactions that have taken place during the year with related parties by the company:

	For the year ended 31st March 2018	For the year ended 31st March 2017	
Sales to related party	NIL	4,90,33,818/-	
Purchase from Related party	NIL	1,11,21,179/-	
Share of profit of related party	NIL	2,81,13,845/-	

- 15. The firm's factory unit at Baddi in Himachal Pradesh is having exemption from Income Tax or a period of 10 years from the date of commencement of production (Year 2010 2011).
- 16. The firm operates in one segment only viz., pharmaceutical formulations.
- 17. Previous year's figures have been regrouped wherever necessary.

As per our report of even dated attached

for CNGSN & Associates

Chartered Accountants

Firm Registration No. 004915S/S200036

For and on behalf of ARGUS SALUD PHARMA LLP

K. PARTHASARATHY

Partner

ICAI membership No:018394

on behalf of

May India Property Private Ltd

Designated Partner

on habott of

Caplin Point Laboratories Ltd

Designated Partner

Jate:25.05.2018
Place:Chennai

